Cargando…
Budget-impact analysis of health care interventions : a practical guide /
The first of its kind for budget-impact analysis, this comprehensive guide provides clear and concise instructions for evaluating the impact that new pharmaceuticals will have on the budget for a specific jurisdiction. The book demonstrates how to create a budget-impact analysis using a simple six-s...
| Clasificación: | Libro Electrónico |
|---|---|
| Autores principales: | , , , , |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Cham, Switzerland :
ADIS,
[2017]
|
| Temas: | |
| Acceso en línea: | Texto completo |
Tabla de Contenidos:
- Author Contributions; Foreword; Preface; Abbreviations; Contents; Chapter 1: Introduction to Budget-Impact Analysis; 1.1 What Is Budget-Impact Analysis?; 1.2 Budget-Impact Analyses Compared with Cost-ƯEffectiveness Analyses; 1.3 Uses of Budget-Impact Analyses; 1.4 Guidelines for Budget-Impact Analyses; 1.5 Overview of Chapters in This Book; Exercises; References; Chapter 2: Determining the Analytic Framework; 2.1 Eligible Population in Jurisdiction; 2.1.1 Impact of Positioning of the New Drug Within the Current Treatment Pathway on Eligible Population Size.
- 2.1.2 Impact of Regulatory Approval on Eligible Population Size2.1.3 Impact of Reimbursement Decisions on Eligible Population Size; 2.1.4 Impact of New Drug Attributes on Initial Population Size; 2.1.5 Impact of New Drug Attributes on Population Size Over Model Time Horizon; 2.2 Budget Holder Time Horizon; 2.3 Potential Use of the New Drug Within the Treatment Mix; 2.4 Budget Holder Cost Perspective; 2.4.1 Service Delivery Cost Versus Reimbursement Rate; 2.4.2 Fixed Versus Variable Costs; 2.4.3 Cost Categories of Interest; 2.5 Compilation of Analytic Framework; Exercises; References.
- Chapter 3: Estimating the Diagnosed, Treated, and Eligible Population3.1 Incident and Prevalent Populations; 3.2 Estimating the Eligible Population Size; 3.3 Data for Identifying the Eligible Population; 3.4 Estimating Population Size by Subgroup; 3.5 Changing Size of the Eligible Population Over the Analysis Time Horizon; 3.5.1 Changing Population Size Regardless of Introduction of the New Drug; 3.5.2 Changing Population Size and Condition Severity Mix due to the Introduction of the New Drug; 3.6 Including Catch-Up Effects for the Prevalent Population.
- 3.7 Which Eligible Population Should We Include in the Budget-Impact Analysis?Exercises; References; Chapter 4: Estimating the Treatment Mix; 4.1 Treatment Shares Without the New Drug in the Treatment Mix; 4.2 Treatment Shares with the New Drug in the Treatment Mix; 4.3 Which Treatment Shares Should We Include in the Budget-Impact Analysis?; Exercises; Reference; Chapter 5: Estimating Treatment-Related Costs; 5.1 Costs for Drug Acquisition; 5.1.1 Co-payments and Coinsurance; 5.1.2 Dispensing Fees; 5.1.3 Dose Levels; 5.1.4 Duration of Treatment; 5.2 Costs for Administering the Drug.
- 5.3 Costs for Diagnostic Tests to Determine Eligibility for the Drug5.4 Costs for Monitoring the Drug for Safety and Efficacy; 5.5 Costs for Treating Side Effects Associated with the Drug; 5.6 Accounting for Differing Treatment Costs in the First and Subsequent Treatment Years; 5.7 Accounting for Other Treatment Costs; 5.8 Estimating Resource Use Changes with the New Drug; Exercises; References; Chapter 6: Estimating Condition-Related Costs; 6.1 Why the New Drug Might Change Condition-Related Costs; 6.2 Estimating Changes in Condition-Related Costs for Incident Populations.